Maternal and Neonatal Outcome after the Use of G-CSF for Cancer Treatment during Pregnancy

Claudia Berends 1,†, Charlotte Maggen 2,3,†, Christianne A. R. Lok 1, Mathilde van Gerwen 1,4, Ingrid A. Boere 5, Vera E. R. A. Wolters 1, Kristel Van Calsteren 6,7, Heidi Segers 8, Marry M. van den Heuvel-Eibrink 4, Rebecca C. Painter 9, Mina Mhallem Gziri 10 and Frédéric Amant 1,2,11,*

Abstract: Data on the use of Granulocyte colony-stimulating factor (G-CSF) in pregnant cancer patients are scarce. The International Network of Cancer, Infertility and Pregnancy (INCIP) reviewed data of 2083 registered patients, 42 pregnant patients received G-CSF for the following indications: recent chemotherapy induced febrile neutropenia (5; 12%), dose dense chemotherapy (28, 67%), polychemotherapy (7, 17%), or prevention of neutropenic fever, which can be an important threat for maternal and fetal survival. However, as evidence is still scarce, physicians are still reluctant to use the G-CSF during pregnancy. In this series, the International Network of Cancer, Infertility and Pregnancy (INCIP) reports on 42 pregnant patients who received G-CSF during oncological treatment. Reported maternal and neonatal complications are acceptable; however, a continuous evaluation of clinical practice is necessary as the limited data in numbers and follow-up do not allow robust conclusions.

Simple Summary: Treatment of pregnant cancer patients should adhere as much as possible to standard treatment protocols in order to safeguard maternal prognosis. The use of Granulocyte colony-stimulating factor (G-CSF) can be indicated for dose dense chemotherapy in high risk breast cancer patients or for the treatment or prevention of neutropenic fever, which can be an important threat for maternal and fetal survival. However, as evidence is still scarce, physicians are still reluctant to the use of G-CSF during pregnancy. In this series, the International Network of Cancer, Infertility and Pregnancy (INCIP) reports on 42 pregnant patients who received G-CSF during oncological treatment. Reported maternal and neonatal complications are acceptable; however, a continuous evaluation of clinical practice is necessary as the limited data in numbers and follow-up do not allow robust conclusions.
in follow-up, there were four children with a motor development delay and two premature infants had a delay in cognitive development. In conclusion, the rate of maternal and neonatal complications are similar to those described in (pregnant) women treated with chemotherapy. Due to small numbers and limited follow-up, rare or delayed effects among offspring exposed to G-CSF in utero cannot be ruled out yet.

**Keywords:** pregnancy; cancer treatment; G-CSF; maternal outcome; neonatal outcome

1. Introduction

The co-occurrence of cancer and pregnancy, estimated to affect 1 in 1000 pregnancies, is expected to rise due to increasing maternal age and incidental findings at the occasion of non-invasive prenatal testing (NIPT) [1,2]. Breast cancer, melanoma, hematological, and cervical cancer are the most common types of cancer diagnosed during pregnancy [1,3]. With the increasing awareness of the feasibility of antenatal cancer treatment, fewer pregnancies are terminated and more pregnant women receive chemotherapy [4]. Whenever possible, oncological treatment during pregnancy should adhere as much as possible to the standard care treatment in non-pregnant patients, in order to safeguard prognosis [5]. However, consequences and safety of some supportive agents that are used as part of current standard therapy, such as Granulocyte Colony-Stimulating Factor (G-CSF), are still subject of discussion.

G-CSF supports the clonal growth of progenitors of neutrophils and regulates the proliferation and differentiation of hematopoietic stem cells. Both in vitro and in vivo studies confirmed transplacental passage of this glycoprotein [6,7]. In oncological care, it is used to treat or prevent prolonged grade 3 (absolute neutrophil count (ANC) < 1.0 × 10⁹/L) and 4 (ANC < 0.5 × 10⁹/L) neutropenia or febrile neutropenia (grade 3–4 neutropenia with fever) in patients receiving chemotherapy [8,9]. In patients with high risk breast cancer, dose dense chemotherapy regimens with G-CSF support, are considered standard of care [5,10].

As available data are still limited to case reports and small case series, use of antenatal G-CSF is still debated [11,12]. Hence, more maternal efficacy and neonatal safety data in larger cohorts are necessary. The aim of this cohort study is to describe the clinical outcomes after use of G-CSF in pregnancy, as part of cancer treatment, in patients and their offspring registered by the International Network of Cancer, Infertility and Pregnancy (INCIP).

2. Materials and Methods

Women with cancer and treated with G-CSF during pregnancy were identified in the INCIP database. The INCIP study has been approved by the ethical committee of the university hospitals of Leuven in Belgium (S25470) and the Erasmus Medical Center in the Netherlands (NL4354607813). The international multicenter study is registered on ClinicalTrials.gov, number NCT00330447. The registry contains both retro- as prospectively collected obstetric and oncological data of women (and their offspring) with a cancer diagnosis in association with pregnancy.

The INCIP database was reviewed for oncological, obstetrical, neonatal, and pediatric data, and missing data were requested from participating hospitals. Pregnancy dating was confirmed in all patients by early ultrasound. To define the efficacy of G-CSF in prevention of chemotherapy-induced neutropenia (dose dense regimen or polychemotherapy regimens with a high risk of neutropenia), results of all available maternal blood samples taken before and during chemotherapy until two weeks after the last administration of G-CSF were retrospectively extracted from patient files. The incidences of maternal neutropenia, leukopenia, anemia, and thrombocytopenia were assessed. Grading of neutropenia, leukopenia, anemia, and thrombocytopenia was defined according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) [8]. Neutropenia was divided
in grade 1–2 (mild) (absolute neutrophil count (ANC) 1.5 × 10⁹/L—lower limit of normal (LLN) or ANC 1.0–1.5 × 10⁹/L, respectively) and grade 3–4 neutropenia (ANC of 1.0–0.5 × 10⁹/L or below 0.5 × 10⁹/L, respectively). Febrile neutropenia was defined as an ANC below 1.0 × 10⁹/L and fever (≥38 °C). Grade 3–4 leukopenia was defined as a white blood cell count (WBC) below 1.0 × 10⁹/L, thrombocytopenia was divided in grade 1–2 (mild) (platelets count (PC) < 150 × 10⁹/L) and grade 3–4 (severe) (PC < 50 × 10⁹/L) [8]. Anemia was defined as grade 1–2 (mild) (hemoglobin (Hb) 8–10 g/dL) and 3–4 (severe) anemia (Hb level below 8.0 g/dL). Oncological data that were collected were tumor type, chemotherapy regimen, gestational age (GA) at the start of chemotherapy and number of G-CSF administrations.

The neonatal blood samples were taken within 48 h after delivery. Neonatal neutropenia was defined as absolute neutrophil count (ANC) < 1.0 × 10⁹/L, leukopenia as white blood cell count (WBC) < 5.0 × 10⁹/L, thrombocytopenia as PC < 15 × 10⁹/L, and anemia as Hb less than 14 g/dL [8,13–17]. Customized percentiles for birthweight (p) were calculated, adjusted for GA at delivery, parity, ethnicity, body mass index (BMI), and sex of the infant [18]. Neonates were small for gestational age (SGA) if the birthweight was below the 10th percentile. Neonatal outcomes of two twin pregnancies were described separately.

In addition, available data of children included in the long-term prospective follow-up study of the INCIP project were collected. In this follow-up study, children underwent a general physical examination by a pediatrician (including clinical neurological evaluation), cognitive (neuropsychological) tests by a psychologist (see Supplementary Table S1 for details), and cardiac evaluation (electrocardiogram (ECG) and echocardiography) by a cardiologist at different time-points. To assess maternal and neonatal outcomes, descriptive analysis (percentages, median and range) were performed.

3. Results

Out of 2083 patients registered by INCIP, 42 patients with cancer during pregnancy were treated with chemotherapy and G-CSF (Figure 1). The majority of patients was diagnosed with breast cancer (n = 35, 83%), followed by non-Hodgkin lymphoma (n = 5, 5%), Ewing sarcoma (n = 1, 1%), and acute lymphocytic leukemia (ALL) (n = 1, 1%) (Table 1).

![Figure 1. Study Flow Chart.](image-url)
Table 1. Maternal characteristics ($n = 42$).

| Maternal Characteristics | Median | Range |
|--------------------------|--------|-------|
| Age at diagnosis (years) | 34     | 19–47 |
| BMI at booking (kg/m$^2$) * | 25.9   | 18.3–36.9 |

| Number | %       |
|--------|---------|
| Ethnicity |        |
| Caucasian | 32 | 76.2 |
| Non-caucasian | 6 | 14.3 |
| Not reported | 4 | 9.5 |

| Type of malignancy |          |        |
|--------------------|----------|--------|
| Breast cancer | 35 | 83.3 |
| Non Hodgkin lymphoma | 5 | 11.9 |
| Ewing sarcoma | 1 | 2.4 |
| Acute lymphocytic leukemia | 1 | 2.4 |

| Treatment modality |          |        |
|--------------------|----------|--------|
| Chemotherapy | 28 | 66.7 |
| Chemotherapy + surgery | 14 | 33.3 |

| Chemotherapy |          |        |
|--------------|----------|--------|
| Anthracycline-based | 18 | 42.9 |
| Anthracycline-based with taxanes | 15 | 35.7 |
| Other ** | 9 | 21.4 |

| Median | Range |        |        |
|--------|-------|--------|--------|
| Gestational age at first chemo (weeks) | 22 | 11–36 |
| Cycles of chemotherapy during pregnancy | 6 | 1–16 |
| Administrations of G-CSF | 4 | 1–16 |

| Indication G-CSF |          |        |
|------------------|----------|--------|
| Prophylactic in dose dense chemotherapy | 28 | 66.7 |
| Prophylactic in polychemotherapy regimen | 7 | 16.7 |
| Prophylactic before delivery | 2 | 4.8 |
| Following chemotherapy-induced neutropenia | 5 | 11.9 |

| Type of G-CSF |          |        |
|---------------|----------|--------|
| Pegfilgrastim | 28 | 66.7 |
| Lipefilgrastim | 8 | 19.1 |
| Filgrastim | 3 | 7.1 |
| Not reported | 3 | 7.1 |

* for 5 patients, BMI was not available. ** Other chemotherapy regimens include rituximab, doxorubicin, cyclophosphamide, vincristine, prednisone (R-CHOP), etoposide, cisplatin (EP), vincristine, ifosfamide, doxorubicin, etoposide (VIDE), rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone (R-ACVPB), epirubicin, cyclophosphamide, paclitaxel, carboplatinum (EC+TC), ifosfamide, etoposide, without methotrexate during pregnancy (VIM), and hyper-CVAD course A (cyclophosphamide, vincristine, doxorubicin, cytarabine, no Methotrexate during pregnancy).

3.1. Treatment

The median GA at the start of chemotherapy was 22 weeks (range 11–36). One patient started chemotherapy for stage 3 breast cancer at 11 weeks of gestation and delivered of twins without malformations, in all other patients chemotherapy was initiated after 13 weeks of gestation. Both short-acting (filgrastim) and long-acting G-CSF (pegfilgrastim, lipefilgrastim) were administered for the following indications:

- Long-acting G-CSF was mostly given as part of a dose dense schedule ($n = 28$; 67%).
- Five patients (12%) developed grade 3–4 neutropenia (including one patient with neutropenic fever) after one to three cycles of 3-weekly chemotherapy (without G-CSF). Two of them received filgastrim during the acute episode of neutropenia and...
all five patients had long-acting G-CSF with the subsequent chemotherapy (without treatment delay) administrations in prevention of febrile neutropenia or dose delays.

- Seven women (7%) received long-acting G-CSF following ‘high risk’ polychemotherapy for Non Hodgkin lymphoma (n = 4), Ewing sarcoma (n = 1) or ALL (n = 1).
- Long-acting G-CSF (pegfilgastrim) was given prophylactically after the last chemotherapy before delivery in two women (5%).

3.2. Maternal Blood Results

Blood results of 24 women who received dose dense chemotherapy were registered (Table 2). Uncomplicated neutropenia grade 3–4 occurred in three women (13%) with breast cancer, but all recovered within five days. There were no reports of febrile neutropenia, nor thrombocytopenia. Mild anemia occurred in 14 women (58%) and severe anemia in two (8%) women.

| Maternal Blood Results | Total n * | Grade 1–2 | Grade 3–4 |
|------------------------|-----------|-----------|-----------|
|                        | n   | %   | n   | %   | n   | %   |
| Neutropenia            | 5   | 21  | 2   | 8   | 3   | 13  |
| Leukopenia *           | 4   | 17  | 2   | 8   | 2   | 8   |
| Thrombocytopenia       | 0   | 0   | 0   | 0   | 0   | 0   |
| Anemia                 | 16  | 67  | 14  | 58  | 2   | 8   |

* one patient had grade 3 neutropenia (0.58 × 10⁹/L) without leukopenia (3.2 × 10⁹/L).

Three patients with available blood counts received long-acting G-CSF as part of intense polychemotherapy with a high risk for neutropenia. One patient suffered from a pancytopenia severe anemia, severe thrombocytopenia, and WBC < 0.1 × 10⁹/L following vincristine, ifosfamide, doxorubicin, etoposide (VIDE) chemotherapy. Two patients received rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) with pegfilgastrim and did not develop hematological toxicities, except for mild anemia in one patient.

3.3. Obstetric Outcome

The obstetric outcomes of 40 singleton pregnancies are described in Table 3. One patient developed febrile neutropenia and secondary pharyngitis following the first course of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy (without G-CSF). Three other patients had a maternal infection requiring antibiotics (two patients with pneumonia, one with a postpartum systemic infection) without leukopenia/neutropenia. An earlier mentioned patient developed a pancytopenia and chorio-amnionitis (without any prior invasive prenatal procedures) and spontaneously delivered a growth-restricted stillborn neonate at a GA of 23 weeks. All other 41 pregnancies ended in live births (including two twin pregnancies). Labor was induced in 18 patients (45%), mostly because of maternal therapy planning (78%). Of the 19 pregnancies that ended pre-term (49%), 12 had a planned delivery, of whom 8 (67%) for therapy planning. The seven other women delivered preterm after spontaneous onset of labor. In total, 23 women (55%) delivered within 3 weeks after the last chemotherapy administration, of whom 11 women (25%) delivered within two weeks (7 spontaneous labors, two emerging obstetrical reasons, two planned deliveries for oncological treatment). Emergency caesarean sections were performed in three women because of pre-eclampsia, fetal distress, and prolonged second stage of labor, respectively.
Table 3. Obstetric outcomes (n = 40, all singleton pregnancies).

| Obstetric Outcomes            | n   | %   |
|-------------------------------|-----|-----|
| Live birth                    | 39  | 97.5|
| Still Birth                   | 1   | 2.5 |

| Gestational age at delivery (n = 39 *) |       |     |
|---------------------------------------|-------|-----|
| ≥37 weeks (a term)                    | 20    | 51.3|
| <37 weeks (pre term)                  | 19    | 48.7|

| Onset of labor                     |       |     |
|------------------------------------|-------|-----|
| Spontaneous                        | 13    | 32.05|
| Induction of labor                 | 18    | 45.0|
| Cesarean section                   | 9     | 22.5|
| Emergency (fetal distress)         | 2     | 22.2|
| Elective (all for obstetrical reason **) | 7 | 77.8|

| Reason induction of labor (n = 18) |       |     |
|------------------------------------|-------|-----|
| Obstetrical reason ***             | 1     | 5.6 |
| Therapy planning                   | 14    | 77.8|
| Deterioration of maternal condition| 2     | 11.1|
| Other                              | 1     | 5.6 |

| Mode of delivery                   |       |     |
|------------------------------------|-------|-----|
| Vaginal delivery                   | 27    | 67.5|
| Assisted vaginal delivery          | 2     | 5.0 |
| Elective Cesarean section          | 8     | 20.0|
| Emergency cesarean section         | 3     | 7.5 |

| Complications                      |       |     |
|------------------------------------|-------|-----|
| Maternal infection (including 1 chorioamnionitis) | 4 (1 postpartum) | 10.0 |
| Gestational diabetes               | 1     | 2.5 |
| Preeclampsia                       | 1     | 2.5 |
| Maternal neutropenia / leukopenia  | 7     | 17.5|
| PPROM or preterm contractions      | 9     | 22.5|
| Stillbirth                         | 1     | 2.5 |
| Postpartum hemorrhage              | 2     | 5.0 |

* 1 stillbirth was excluded. ** placenta previa, repeat cesarean section, breech. *** hypertension, preeclampsia, cholestasis, diabetes, premature rupture of membranes.

3.4. Neonatal Outcome

Nineteen singleton livebirths were born preterm (19 of 39, 49%). Of all singleton neonates, 11 (28%) were SGA. Thirteen neonates (41%) were admitted to the NICU, mainly because of prematurity (81%) (Table 4). There were no reports of neonates with leukopenia or neutropenia and there were two neonates, born term, with anemia (Hb measurements between 12.0 and 13.5 g/dL). One neonate born one day after prenatal polychemotherapy by emergency cesarean section at a GA of 29 weeks for fetal distress, suffered from a Klebsiella sepsis with thrombocytopenia and intravascular coagulation leading to microthrombi. Two other neonates, delivered preterm within 3.5 weeks following chemotherapy, were treated with antibiotics because of systemic infection. Two neonates had a congenital malformation: one neonate prenatally exposed to 5-FU, epirubicin, cyclophosphamide (FEC) (+ pegfilgastrim) and docetaxel from 20 weeks of pregnancy onwards, was born with an absent uvula. The other neonate, prenatally exposed to dose dense doxorubicin, cyclophosphamide (AC) between 30 and 36 weeks of gestation, had a severe pulmonary valve stenosis, diagnosed after birth. It was successfully treated with balloon dilatation at the age of 1 month. In both cases, there were no maternal risk factors for congenital malformations, nor neonatal chromosomal abnormalities reported.

One woman delivered of healthy twins following induced labor at 37 weeks after dose dense epirubicin, cyclophosphamide (EC) and paclitaxel weekly. Another twin pregnancy ended in a spontaneous delivery at 29 weeks after dose dense EC and paclitaxel weekly.
Table 4. Neonatal outcomes (n = 39, all singleton live births).

| Neonatal Outcomes                              | Median | Range      |
|-----------------------------------------------|--------|------------|
| Birth weight (grams)                          | 2855   | 850–3780   |
| Customized birthweight percentile             |        |            |
| <10                                           | 11     | 28.2       |
| 11–49                                         | 18     | 46.1       |
| 50–89                                         | 8      | 20.5       |
| >90                                           | 2      | 5.1        |
| APGAR at 5 min                                |        |            |
| 4                                             | 1      | 2.6        |
| 9                                             | 8      | 20.5       |
| 10                                            | 29     | 74.4       |
| Not reported                                  |        |            |
| Congenital malformation                       |        |            |
| yes                                           | 2      | 5.1        |
| no                                            | 37     | 94.8       |
| Admission neonatal care unit                  |        |            |
| yes                                           | 16     | 41.0       |
| no                                            | 20     | 51.3       |
| Not reported                                  | 3      | 7.7        |
| Reason admission neonatal care unit           |        |            |
| Prematurity                                   | 13     | 81.3       |
| Observation because of maternal chemotherapy  | 1      | 6.3        |
| Other                                         | 2      | 12.5       |
| Neonatal blood results                        |        |            |
| Leukopenia *                                  | 0      | 0          |
| Neutropenia **                                | 0      | 0          |
| Thrombocytopenia ***                          | 1      | 5.8        |
| Anemia ****                                   | 2      | 10         |
| Neonatal complications                        |        |            |
| Hyperbilirubinemia                            | 2      | 5.2        |
| Neonatal sepsis                               | 3      | 7.7        |
| First degree cerebral bleeding related to prematurity | 1  | 2.6       |

* Available WBC n = 24, ** Available ANC n = 12, *** Available PC n = 18; **** Available hemoglobin n = 20.

3.5. Pediatric Outcome

Twenty-one children participated in the follow-up study of the INCIP. The median follow-up was 18 months (range 2 months–9 years) (Supplementary Table S1). No neurological or functional cardiac abnormalities were observed. In four children (19%), born at a median GA of 38 weeks, motor development was delayed at 11 months (n = 1) and 18 months (n = 3). One child had a hip dysplasia and one child had a preferential posture, which both required physiotherapy. Eventually, all four children had a normal motor development at 18 months and 36 months of follow-up according to standardized and clinical measures of development. In four children (19%), delayed cognitive development was identified; one child born at a GA of 29 weeks and 2 days, was assessed at 18 months of age and had an appropriate cognitive development, but delayed language development. The child was referred to a speech-language therapist. Two children (10%), both born after GA of 37 weeks, had a delay in cognitive development at 18 months of age, but cognitive development was appropriate at 3 and 6 years of age according to standardized and clinical measures of neurocognitive development. Another child, prenatally exposed to nicotine, cannabis and chemotherapy, was born at a GA of 35 weeks and 4 days with a birthweight of 2060 g (P 5.1). The child had an appropriate cognitive development at 18 months of follow-up, but cognitive and language development was delayed at 3 years of age. At the age of 3 years, the child also had behavioral and emotional problems and bodyweight.
was above the 97th percentile. The child and parents were referred to a specialized center for childcare.

4. Discussion

In this manuscript, we report the maternal and neonatal outcomes of 42 patients with chemotherapy and G-CSF treatment during pregnancy. In the 24 patients who received dose dense chemotherapy supported with G-CSF, febrile neutropenia did not occur and grade 3–4 maternal neutropenia could often be prevented (n = 3; 13%). There was one stillbirth following maternal pancytopenia and chorio-amnionitis after VIDE chemotherapy, despite administration of G-CSF to prevent hematological toxicity. Two out of 39 singletons had a congenital malformation (5%). Neonatal neutropenia did not occur and there were no major abnormalities reported in the clinical follow-up of 21 children.

Of note, G-CSF in pregnancy should only be considered when there is a clear indication. There is no evidence to support prophylactic use of the drug prior to delivery, as done in two cases in this series. Outside pregnancy, the addition of G-CSF to chemotherapy improves overall survival, as it minimizes treatment delays and allows dose-dense chemotherapy regimens leading to an increased disease control [19]. The risk of neutropenic fever during chemotherapy in pregnancy is unknown, but may be lower than outside pregnancy owing to the more rapid clearance of chemotherapy and larger distribution volume in pregnancy [20]. However, the consequences of febrile neutropenia in pregnancy threaten both maternal and fetal survival. G-CSF is usually well tolerated, with medullary bone pain being the most frequently reported side effect [21]. Other less common adverse effects include headaches, generalized musculoskeletal pain and, very rare, an anaphylactoid-like reaction. An increased risk of secondary hematological malignancies in cancer patients receiving G-CSF is suggested, although this association has not been found consistently and might be also related to increased doses of chemotherapeutic agents with leukemogenic potential [19,22]. Moreover, patients with severe congenital neutropenia treated with G-CSF, are at long-term risk to develop myelodysplastic syndrome and acute myeloid leukemia [23]. Another concern is that G-CSF might contribute to a hypercoagulable state and thrombosis, besides other factors in this high risk population (pregnancy, cancer, surgery, and chemotherapy) [24,25].

Physicians are hesitant to use antenatal G-CSF as it crosses the placenta and could affect the development of the unborn child, including spontaneous miscarriage and congenital malformations [26]. Although there are reassuring data on G-CSF use in neonates, these data cannot just be generalized to the fetus because of the immature fetal metabolism and organs [27]. The neonatal consequences of G-CSF in pregnancy have mainly been investigated for treatment of neutropenia unrelated to chemotherapy. Four large studies and five case reports, with in total 162 pregnancies, have investigated G-CSF in pregnancy for treatment of chronic neutropenia [26,28–35]. In these studies, G-CSF administration ranged from the first to the third trimester. None of these studies found an increased incidence of fetal death or congenital malformations. In four pregnancies where G-CSF was used because of ritodrine (a tocolytic drug)-induced neutropenia, no maternal or neonatal adverse effects of G-CSF were found [36,37]. Furthermore, it is suggested that G-CSF can be administered in pregnancy or lactation in order to mobilize stem cells for stem cell transplantation [38]. Although these data are reassuring concerning G-CSF use, patients were not comparable to our cohort as they did not receive (dose dense) chemotherapy, which is an extra risk factor for adverse maternal and neonatal outcome.

Neonates born from 12 mothers who received G-CSF just before delivery were shown to have increased neutrophil counts compared to a control group [7]. La Nasa et al. reported an incidence of neonatal neutropenia and leukopenia after chemotherapy and long-acting G-CSF of only 4% (n = 24 and n = 26, respectively) [15]. Using the same definitions, we did not observe any neonatal neutropenia or leukopenia in this series. These results suggest that G-CSF may not only be beneficial for the mother, but also for the neonate as the prevention of leukopenia will reduce the risk of infection. In this series, there were three
neonates with an early onset systemic infection without maternal neutropenia. All three neonates were born preterm (between GA of 28–34 weeks) and were SGA, both risk factors for neonatal sepsis [39].

The incidence of SGA in this population was 28% and 41% of neonates were admitted to the NICU, mostly because of prematurity, which is comparable to large cohort studies on pregnant women with cancer (21% and 41%, respectively) [4]. Major congenital malformations are estimated to occur in 255 out of 10,000 births (2.5%) [40]. In this series, two birth defects (5%) were reported: pulmonary valve stenosis and absent uvula. The latter is an extremely rare condition and based on the registered data it is not clear whether this malformation was isolated or part of a congenital syndrome. Of note, G-CSF and chemotherapy were administered in all patients after the most vulnerable period of fetal organogenesis (between 2 and 8 weeks following conception) [41]. As G-CSF has no cytotoxic mechanism of action, it is assumable that the causality with congenital malformations is unlikely, but safety in the first trimester cannot be guaranteed based on this series. In comparison, the occurrence of congenital malformation in the pregnant cancer population is reported to be 4% (2% major and 2% minor malformations according to EUROCAT) [4,42]. In total, 22 (3.0%) major and 13 (1.8%) minor congenital malformations were seen in the offspring of 726 women treated with chemotherapy in the second and third trimester of pregnancy (INCIP data not published).

The rate of severe neutropenia following dose dense chemotherapy was 13% (3/24), which is comparable with the reported rates in the non-pregnant population (14.9%) [43]. However, the decrease in leukocytes following chemotherapy in pregnancy might be underestimated when reference counts from the general population are used, as during pregnancy the leukocyte count significantly increases physiologically [44]. The observed rate of severe anemia was higher compared to the non-pregnant population (8% vs. 2%), however the incidence of mild anemia was comparable (58% vs. 66%) [43]. Of note, gestational changes induce a ‘physiological dilutional’ anemia, resulting in reduced physiological Hb levels (10 to 11 g/dL), but severe anemia is unlikely to be explained by pregnancy alone [45]. Of note, there was no report of febrile neutropenia nor thrombocytopenia following dose dense treatment in this series.

Major neurologic or functional cardiac abnormalities were not found during follow-up of 21 children. Earlier studies showed that prematurity is a predictor for worse cognitive outcome rather than prenatal exposure to cancer treatment [46]. In addition to this series, no significant difference in incidence of behavioral problems, asthma, eczema, or problems with speech were found between 29 exposed children, with a mean follow-up of 54 months, and 114 non-exposed children [12]. Of note, available data are still too limited to make robust conclusions and highlights the need for continuous follow-up, especially as children born SGA seems to be at risk for neurological dysfunction [47].

The maternal and neonatal outcomes in this series are in line with previously published cohort studies of 10 and 34 pregnant women that received G-CSF during oncological treatment [11,12]. A strength of this study was the information on pediatric outcomes after antenatal G-CSF, collected as part of an international registration study. The retrospective nature of the registration study incorporates inevitably missing data. Reported numbers are too low to distinguish consequences of short- and long-acting G-CSF separately. The follow-up of children in this series (maximum 9 years) is also too short to learn about childhood malignancies. Research in larger cohorts remains indispensable to confirm the independent benefit and low incidence of adverse events of G-CSF in the pregnant population and their offspring.

5. Conclusions

Since we did not observe any marked increase in perinatal complications and the outcomes of this series are in line with available literature, we conclude with caution that the use of G-CSF during pregnancy can be considered when this is clinically indicated for maternal oncological treatment. However, our study was not powered for perinatal com-
lications with low incidence, such as thrombosis, or delayed long-term effects, including secondary malignancies. G-CSF should therefore continue to be administered with caution, and only for indications which provide proven benefit for survival and cancer prognosis, and preferably in the context of ongoing registration studies. These data further contribute to the policy to treat pregnant cancer patients as much as possible as non-pregnant cancer patients in order to safeguard cancer outcomes.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/2072-694/13/6/1214/s1, Supplementary Table S1: Pediatric follow-up of children prenatally exposed to G-CSF (n = 21).

**Author Contributions:** Conceptualization, K.V.C. and F.A.; Data curation, C.B., C.M., C.A.R.L., M.v.G., I.A.B., V.E.R.A.W., K.V.C., M.M.v.d.H.-E., R.C.P., M.M.G. and F.A.; Formal analysis, C.B., C.M., C.A.R.L. and M.v.G.; Funding acquisition, K.V.C. and F.A.; Investigation, C.B., C.M., C.A.R.L., M.v.G., I.A.B., V.E.R.A.W., K.V.C. and F.A.; Methodology, C.B., C.M., C.A.R.L., M.v.G., M.M.v.d.H.-E. and F.A.; Supervision, K.V.C., M.M.v.d.H.-E. and F.A.; Writing—original draft, C.B., C.M., C.A.R.L. and M.v.G.; Writing—review & editing, I.A.B., V.E.R.A.W., K.V.C., H.S., M.M.v.d.H.-E., R.C.P., M.M.G. and F.A. All authors contributed to writing—review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This project is funded by the European Union’s Horizon 2020 research and innovation program under grant agreement No 647047, “Kom Op Tegen Kanker” (Stand up to Cancer), the Flemish cancer society, “Stichting tegen Kanker” and Koningin Wilhelmina Fonds under project number 10094. Frédéric Amant is senior clinical investigator of the FWO.

**Institutional Review Board Statement:** The INCIP study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Ethics Committee of university hospitals of Leuven in Belgium (S25470, date of approval 23-05-2014) and the Erasmus Medical Center in the Netherlands (NL4354607813, date of approval 26-05-2014).

**Informed Consent Statement:** Informed consent was obtained from all patients or their parents involved in the study.

**Data Availability Statement:** The data presented in this study are available upon request from the corresponding author. The data are not publicly available.

**Acknowledgments:** We are grateful to the European Society of Gynaecological Oncology (ESGO) for their continued support. We thank all participating centers, physicians, outpatient clinics, and all paramedical staff involved in INCIP registration. The list of participating centers of INCIP can be found on www.cancerinpregnancy.org (accessed on 10 December 2020).

**Conflicts of Interest:** There are no conflicts of interest to declare.

**Abbreviations**

INCIP: International Network on Cancer, Infertility and Pregnancy. G-CSF: Granulocyte colony-stimulating factor; NIPT: non-invasive prenatal testing; SGA: Small for Gestational Age.

**References**

1. Smith, L.H.; Danielsen, B.; Allen, M.E.; Cress, R. Cancer associated with obstetric delivery: Results of linkage with the California cancer registry. *Am. J. Obstet. Gynecol.* 2003, 189, 1128–1135. [CrossRef]

2. Amant, F.; Verheecke, M.; Wlodarska, I.; Dehaspe, L.; Brady, P.; Brison, N.; Van Den Bogaert, K.; Dierickx, D.; Vandecaveye, V.; Tousseyn, T.; et al. Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. *JAMA Oncol.* 2015, 1, 814–819. [CrossRef]

3. Cottreau, C.M.; Dashevsky, I.; Andrade, S.E.; Li, D.K.; Nekhlyudov, L.; Raebel, M.A.; Ritzwoller, D.P.; Partridge, A.H.; Pawloski, P.A.; Toh, S. Pregnancy-Associated Cancer: A U.S. Population-Based Study. *J. Women’s Health* 2019, 28, 250–257. [CrossRef]

4. de Haan, J.; Verheecke, M.; Van Calsteren, K.; Van Calster, B.; Shmakov, R.G.; Mhallem Gziri, M.; Halaska, M.J.; Fruscio, R.; Lok, C.A.R.; Boere, I.A.; et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: A 20-year international cohort study of 1170 patients. *Lancet Oncol.* 2018, 19, 337–346. [CrossRef]
5. Loibl, S.; Schmidt, A.; Gentilini, O.; Kaufman, B.; Kuhl, C.; Denkert, C.; von Minckwitz, G.; Parokonnaya, A.; Stensheim, H.; Thomssen, C.; et al. Breast Cancer Diagnosis During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA Oncol. 2015, 1, 1145–1153. [CrossRef]

6. Gregor, H.; Egarter, C.; Levin, D.; Sternberger, B.; Heinze, G.; Leitich, H.; Reisenberger, K. The Passage of Granulocyte-Macrophage Colony-Stimulating Factor Across the Human Placenta Perfused In Vitro. J. Soc. Gynecol. Invest. 1999, 6, 307–310. [CrossRef]

7. Calhoun, D.A.; Rosa, C.; Christensen, R.D. Transplacental passage of recombinant human granulocyte colony-stimulating factor in women with an imminent preterm delivery. Am. J. Obstet. Gynecol. 1996, 174, 1306–1311. [CrossRef]

8. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available online: https://ctep.cancer.gov/ (accessed on 10 December 2020).

9. Smith, T.J.; Bohlke, K.; Armitage, J.O. Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline Update. J. Oncol. Pract. 2015, 11, 511–513. [PubMed]

10. Early Breast Cancer Trialists’ Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. Lancet 2019, 393, 1440–1452.

11. Cardonick, E.; Gilmandyar, D.; Somer, R.A. Maternal and Neonatal Outcomes of Dose-Dense Chemotherapy for Breast Cancer in Pregnancy. Obstet. Gynecol. 2012, 120, 1267–1272. [CrossRef] [PubMed]

12. Cardonick, E.; Irfan, F.; Torres, N. The Use of Neupogen (Filgrastim) or Neulasta (Pegfilgrastim) during Pregnancy When Chemotherapy Is Indicated for Maternal Cancer Treatment. J. Cancer Ther. 2012, 3, 157–161. [CrossRef]

13. Schmutz, N.; Henry, E.; Jopling, J.; Christensen, R.D. Expected ranges for the neutrophil concentrations of neonates: The Manroo and Mouzzino charts revisited. J. Perinatol. 2008, 28, 275–281. [CrossRef] [PubMed]

14. Lyman, G.H.; Barron, R.L.; Natoli, J.L.; Miller, R.M. Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. Crit. Rev. Oncol. Hematol. 2012, 81, 296–308. [CrossRef]

15. van Hasselt, J.G.; van Calsteren, K.; Heyns, L.; Han, S.; Mhallem Gziri, M.; Schellens, J.H.; Beijnen, J.H.; Huitema, A.D.; Amant, F. Optimizing anticancer drug treatment in pregnant cancer patients: Pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann. Oncol. 2014, 25, 2059–2065. [CrossRef] [PubMed]

16. Smith, T.J.; Khatchersessian, J.; Lyman, G.H.; Ozer, H.; Armitage, J.O.; Baldiucci, L.; Bennett, C.L.; Cantor, S.B.; Crawford, J.; Cross, S.J.; et al. 2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline Update. J. Clin. Oncol. 2007, 25, 3187–3205. [CrossRef]

17. Jabagi, M.J.; Vey, N.; Goncalves, A.; Le Tri, T.; Zureik, M.; Dray-Spira, R. Risk of secondary hematologic malignancies associated with breast cancer chemotherapy and G-CSF support: A nationwide population-based cohort. Br. J. Haematol. 2012, 159, 196–199. [CrossRef] [PubMed]

18. Rosenberg, PS.; Zeidler, C.; Bolyard, A.A.; Alter, B.P.; Bonilla, M.A.; Boxer, L.A.; Dror, Y.; Kinsey, S.; Link, D.C.; Newburger, P.E.; et al. Stable long-term risk of leukemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br. J. Haematol. 2010, 150, 196–199. [CrossRef] [PubMed]

19. Leblanc, R.; Roy, J.; Demers, C.; Vu, L.; Cantin, G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant. 1999, 23, 991–996. [CrossRef]

20. Kaptan, K.; Beyan, C.; Ifran, A. Granulocyte colony-stimulating factor and hypercoagulability. Int. J. Cardiol. 2008, 131, 129. [CrossRef] [PubMed]

21. Boxer, L.A.; Bolyard, A.A.; Kelley, M.L.; Marrero, T.M.; Phan, L.; Bond, J.M.; Newburger, P.E.; Dale, D.C. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet. Gynecol. 2015, 125, 197–203. [CrossRef] [PubMed]

22. Carr, R.; Modi, N.; Dore, C. G-CSF and GM-CSF for treating or preventing neonatal infections. Cochrane Database Syst. Rev. 2003, 2003, CD003066. [CrossRef]

23. Cottle, T.E.; Fier, C.J.; Donadieu, J.; Kinsey, S.E. Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Semin. Hematol. 2002, 39, 134–140. [CrossRef]

24. Dale, D.C.; Cottle, T.E.; Fier, C.J.; Bolyard, A.A.; Bonilla, M.A.; Boxer, L.A.; Cham, B.; Freedman, M.H.; Kannourakis, G.; Kinsey, S.E.; et al. Severe chronic neutropenia: Treatment and follow-up of patients in the Severe Chronic Neutropenia International Registry. Am. J. Hematol. 2003, 72, 82–93. [CrossRef] [PubMed]

25. Zeidler, C.; Grote, U.A.; Nickel, A.; Brand, B.; Carlsson, G.; Cortesao, E.; Dufour, C.; Duhem, C.; Notheis, G.; Papadaki, H.A.; et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry. Haematologica 2014, 99, 1395–1402. [CrossRef]
31. Kaufmann, S.J.; Sharif, K.; Sharma, V.; McVerry, B.A. Term delivery in a woman with severe congenital neutropenia, treated with growth colony stimulating factor. *Hum. Reprod.* 1998, 13, 498–499. [CrossRef]

32. Ohba, T.; Yoshimura, T.; Araki, M.; Miyoshi, J.; Yonemura, Y.; Matsuura, K.; Okamura, H. Aplastic anemia in pregnancy: Treatment with cyclosporine and granulocyte-colony stimulating factor. *Acta Obstet. Gynecol. Scand.* 1999, 78, 458–461.

33. Sangalli, M.R.; Peek, M.; McDonald, A. Prophylactic granulocyte colony-stimulating factor treatment for acquired chronic severe neutropenia in pregnancy. *Aust. N. Z. J. Obstet. Gynaecol.* 2001, 41, 470–471. [CrossRef]

34. Fung, Y.L.; Pitcher, L.A.; Taylor, K.; Minchinton, R.M. Managing passively acquired autoimmune neonatal neutropenia: A case study. *Transfus. Med.* 2005, 15, 151–155. [CrossRef] [PubMed]

35. Wang, H.; Sun, J.-L.; Zhang, Z.-L.; Pei, H.-H. Pregnancy complicated with agranulocytosis. *Medicine* 2016, 95, e5717. [CrossRef]

36. Kikkawa, M.; Matsubara, S.; Takatoku, M.; Kuwata, T.; Ohkuchi, A.; Izumi, A.; Watanabe, T.; Suzuki, M. Granulocyte-colony stimulating factor for the treatment of ritodrine-induced neutropenia. *J. Obstet. Gynaecol. Res.* 2008, 34, 286–290. [CrossRef]

37. Wang, C.Y.; Lai, Y.J.; Hwang, K.S.; Chen, C.H.; Yu, M.H.; Chen, H.T.; Su, H.Y. Successful treatment with granulocyte-colony stimulating factor for ritodrine-induced neutropenia in a twin pregnancy. *Taiwan. J. Obstet. Gynecol.* 2016, 55, 738–740. [CrossRef] [PubMed]

38. Pessach, I.; Shimoni, A.; Nagler, A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: What do we know? *Hum. Reprod. Update* 2013, 19, 259–267. [CrossRef] [PubMed]

39. Shane, A.L.; Sánchez, P.J.; Stoll, B.J. Neonatal sepsis. *Lancet* 2017, 390, 1770–1780. [CrossRef]

40. Prevalences Rates of All Congenital Malformations by Year. Available online: https://eu-rd-platform.jrc.ec.europa.eu/ (accessed on 10 December 2020).

41. Cardonick, E.; Iacobucci, A. Use of chemotherapy during human pregnancy. *Lancet Oncol.* 2004, 5, 283–291. [CrossRef]

42. Eurocat. Malformation Coding Guides. Available online: http://www.eurocat-network.eu (accessed on 10 February 2021).

43. Del Mastro, L.; De Placido, S.; Bruzzi, P.; De Laurentiis, M.; Boni, C.; Cavazzini, G.; Durando, A.; Turletti, A.; Nistico, C.; Valle, E.; et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 × 2 factorial, randomised phase 3 trial. *Lancet* 2015, 385, 1863–1872. [CrossRef] [PubMed]

44. Lurie, S.; Rahamim, E.; Piper, I.; Golan, A.; Sadan, O. Total and differential leukocyte counts percentiles in normal pregnancy. *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2008, 136, 16–19. [CrossRef] [PubMed]

45. Pavord, S.; Daru, J.; Prasannan, N.; Robinson, S.; Stanworth, S.; Girling, J.; on behalf of the BSH Committee. UK guidelines on the management of iron deficiency in pregnancy. *Br. J. Haematol.* 2020, 188, 819–830. [CrossRef] [PubMed]

46. Amant, F.; Vandenbroucke, T.; Verheecke, M.; Fumagalli, M.; Halaska, M.J.; Boere, I.; Han, S.; Gziri, M.M.; Peccatori, F.; Rob, L.; et al. Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. *N. Engl. J. Med.* 2015, 373, 1824–1834. [CrossRef] [PubMed]

47. Vollmer, B.; Edmonds, C.J. School Age Neurological and Cognitive Outcomes of Fetal Growth Retardation or Small for Gestational Age Birth Weight. *Front. Endocrinol.* 2019, 10, 186. [CrossRef] [PubMed]